Teva Announces Pricing and Underwriting of Multi-Tranche Senior Notes Totaling ā¬1.5B and $3.2B
TEVA PHARMACEUTICAL INDUSTRIES LTD
Subscribe to track TEVA
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š¢ Teva Pharmaceutical Industries Ltd ($TEVA)
Filing Type: Form 8-K (Other Events / Regulation FD) Event Date: September 9, 2026 Filing Date: September 11, 2026
Summary: Teva entered into an Underwriting Agreement for the offer and sale of multi-tranche Senior Notes across EUR and USD tranches, unconditionally guaranteed by Teva Pharmaceutical Industries Limited: ā¢ Euro Notes (Teva Finance II): ā¬1.0B 4.250% due 2033 (at 98.756%) and ā¬500M 4.625% due 2036 (at 98.327%) ā¢ USD Notes (Teva Finance III): $1.0B 5.500% due 2034 (at 98.659%) and $1.0B 5.750% due 2037 (at 98.520%) ā¢ USD Notes (Teva Finance IV): $1.2B 5.250% due 2032 (at 98.993%)
Expected Settlement: September 16, 2026.
Comprehensive Analysis
Overview & Event Summary
On September 11, 2026, Teva Pharmaceutical Industries Limited filed a Current Report on Form 8-K under Items 7.01, 8.01, and 9.01 to disclose the pricing and entry into an Underwriting Agreement for a multi-currency senior notes offering through its finance subsidiaries.
Key Terms of the Offering
On September 9, 2026, the Issuers and Teva (as Guarantor) entered into an Underwriting Agreement with BNP Paribas, Citigroup Global Markets, Goldman Sachs Bank Europe SE, and J.P. Morgan:
-
Teva Pharmaceutical Finance Netherlands II B.V.:
- ā¬1,000,000,000 4.250% Senior Notes due 2033 (priced at 98.756% of aggregate principal)
- ā¬500,000,000 4.625% Senior Notes due 2036 (priced at 98.327% of aggregate principal)
-
Teva Pharmaceutical Finance Netherlands III B.V.:
- $1,000,000,000 5.500% Senior Notes due 2034 (priced at 98.659% of aggregate principal)
- $1,000,000,000 5.750% Senior Notes due 2037 (priced at 98.520% of aggregate principal)
-
Teva Pharmaceutical Finance Netherlands IV B.V.:
- $1,200,000,000 5.250% Senior Notes due 2032 (priced at 98.993% of aggregate principal)
Guarantee and Closing
- Guarantor: Unconditionally guaranteed by Teva Pharmaceutical Industries Limited.
- Expected Settlement/Closing Date: September 16, 2026.
- Registration: Registered under the Securities Act pursuant to Form S-3ASR (File No. 333-284770).
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.